Association of miR-125b expression with the promoter hypermethylation of a panel of tumour suppressor genes.

<p>(A)DAPK1 (B) p16 (C) RASSF1A (D) PTEN (E) BRCA1 (F) p14. Positive and negative depicts the presence or absence of promoter hypermethylation of the specified tumour suppressor gene respectively.</p

Association of serum miR-125b and clinicopathological characteristics in epithelial ovarian cancer patients with respect to A)Stage, (B)Lymph node metastasis and (C)Distant metastasis status.

<p>Association of serum miR-125b and clinicopathological characteristics in epithelial ovarian cancer patients with respect to A)Stage, (B)Lymph node metastasis and (C)Distant metastasis status.</p

AUC for ROC curve corresponding to the diagnostic value of miR-125b in EOC.

<p>AUC for ROC curve corresponding to the diagnostic value of miR-125b in EOC.</p

Sequence of mature miR-125b primer used.

<p>Sequence of mature miR-125b primer used.</p

Association between miR-125b expression and clinicopathological characteristics in epithelial ovarian cancer.

<p>Association between miR-125b expression and clinicopathological characteristics in epithelial ovarian cancer.</p

Area under curve (AUC) of receiver operating characteristic (ROC) for miR-125b corresponding to (A)Tumor grade (B)Metastasis (C)Lymph node status and (D)Survival of EOC patients.

<p>Area under curve (AUC) of receiver operating characteristic (ROC) for miR-125b corresponding to (A)Tumor grade (B)Metastasis (C)Lymph node status and (D)Survival of EOC patients.</p

Kaplan Meier survival curve with respect to (A) fold change (B) mucinous and serous histopathological subtypes.

<p>Kaplan Meier survival curve with respect to (A) fold change (B) mucinous and serous histopathological subtypes.</p

Serum expression of miR-125b.

<p>(A) Dot plot showing the relative expression of miR-125b in patients and controls (B) ROC curve for miR-125b exhibiting its diagnostic potential in epithelial ovarian cancer.</p